AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00280592
Drug: Cranberry
RxNorm normalized name: Cranberry
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry essence of cranberry presented as 18 mg of proanthocyanidines sachets of powdered cranberry. Cranberry juice is administered twice a day (in the morning and in the evening).
Trial: NCT01689441
Drug: Calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01853293
Drug: Kudzu extract
RxNorm normalized name: Aminobenzoic Acid/Black Cohosh Extract/Boron/Dong Quai Extract/Ginseng Extract, Korean/Hesperidin/Kudzu Extract/Licorice Extract/Resveratrol/Wild Yam Extract 50 MG-25 MG-25 MCG-25 MG-100 MG-50 MG-25 MG-37.5 MG-0.5 MG-25 MG Oral Capsule
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02260206
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
Trial: NCT03633591
Drug: Tolcapone
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple doses of tolcapone tablets in the fasted state
Trial: NCT03633591
Drug: Tolcapone Modified Release Prototype
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of tolcapone modified release prototype in the fasted state
Trial: NCT06720233
Drug: SAL-0951 tablets
RxNorm normalized name: salicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
Trial: NCT01388153
Drug: Acarbose (Glucobay ODT, BAYG5421)
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken without water
Trial: NCT01388153
Drug: Acarbose (Glucobay ODT, BAYG5421)
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken with water
Trial: NCT01388153
Drug: Acarbose (Glucobay, BAYG5421)
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet; Day 2: oral sucrose load plus Glucobay standard tablet taken with water
Trial: NCT02740959
Drug: Astragalus Polysaccharides 500 mg
RxNorm normalized name: Astragalus polysaccharides
DrugBank: Astragalus mongholicus root polysaccharides (DB17721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PG2 Injection 500 mg PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
Trial: NCT02740959
Drug: Astragalus Polysaccharides 250 mg
RxNorm normalized name: Astragalus polysaccharides
DrugBank: Astragalus mongholicus root polysaccharides (DB17721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PG2 Injection 250 mg PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
Trial: NCT03633591
Drug: Tolcapone Divided Dose
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolcapone (suspension) in equal divided doses in the fasted state
Trial: NCT03633591
Drug: Tolcapone Modified Release Prototype
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of tolcapone modified release prototype (optionally two doses or fed state of prior MR prototype)
Trial: NCT04653389
Drug: Sintilimab Injection
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab Injection is used as neoadjuvant therapy and adjuvant therapy.
Trial: NCT03199950
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol 2dd1mg (08.00am - 10.00pm)
Trial: NCT03113110
Drug: Empagliflozin 10 mg
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PTDM patients on previous antidiabetic treatment (\<40 IU insulin (in some cases plus oral antidiabetics)) receive Empagliflozin, ideally as monotherapy
Trial: NCT04118647
Drug: Wu-Chu-Yu tang
RxNorm normalized name: Yu Jin
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wu-Chu-Yu tang at a rate of 3.0 g three times per day for 28 days.
Trial: NCT01718613
Drug: Vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
Trial: NCT04273516
Drug: Rivaroxaban 2.5 Mg Oral Tablet
RxNorm normalized name: rivaroxaban 2.5 MG Oral Tablet
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet Rivaroxaban 2.5 mg 2 times daily add to standard treatment ASA 80 mg daily
Trial: NCT04273516
Drug: Rivaroxaban placebo tablets
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo tablets add to ASA 80 mg daily that is standard treatment
Trial: NCT01078142
Drug: Temsirolimus, Rituximab, Bendamustin
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase I:~Temsirolimus 25 - 50 - 75mg, day 1,8,15 Bendamustin 90/m2, day 1,2 Rituximab 375/m2, day 1 Phase II at established dose, repeat day 28-42 (max)
Trial: NCT04653389
Drug: TACE
RxNorm normalized name: Tace
DrugBank: Chlorotrianisene (DB00269)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The first TACE and Sintilimab Injection will be initiated simultaneously.
Trial: NCT01126684
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg of atorvastatin once daily for six months
Trial: NCT00894088
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate Mofetil 500 mg Tablet
Trial: NCT00167518
Drug: Triamcinolone acetate
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00919061
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine: 800 mg/m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
Trial: NCT00919061
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg /m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
Trial: NCT00919061
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg PO once a day continuously.
Trial: NCT03518086
Drug: Mirikizumab
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT04639960
Drug: Risperdal
RxNorm normalized name: Risperdal
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Twelve weeks of treatment with a gradual increase of dosage over one week and a gradual decrease over two weeks.
Trial: NCT01801111
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib will be administered at a dose of 100 mg via tablet, orally, once daily in combination with alectinib to participants who progressed on alectinib alone treatment as per treating physician discretion.
Trial: NCT01801111
Drug: Alectinib
RxNorm normalized name: Alectinib
DrugBank: Alectinib (DB11363)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Alectinib will be administered at a dose of 600 milligrams (mg) via capsule, orally, twice daily.
Trial: NCT00938288
Drug: KW-3357
RxNorm normalized name: Antithrombin (human variant kw-3357)
DrugBank: Antithrombin Alfa (DB11166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50IU/mL, IV single dose
Trial: NCT00002519
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03284853
Drug: Netarsudil/Latanoprost 0.02%/0.005%
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical sterile ophthalmic solution
Trial: NCT00235014
Drug: trandolapril
RxNorm normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg QD
Trial: NCT00235014
Drug: trandolapril/verapamil
RxNorm normalized name: TRANDOLAPRIL/VERAPAMIL
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180/2 mg QD
Trial: NCT00235014
Drug: verapamil
RxNorm normalized name: Verapamil
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SR 240 mg QD
Trial: NCT04163185
Drug: AXS-07 (MoSEIC meloxicam and rizatriptan)
RxNorm normalized name: AX
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AXS-07 tablet taken once upon the earliest onset of migraine pain.
Trial: NCT04369664
Drug: Ezetimibe 10mg
RxNorm normalized name: EZETIMIBE 10MG TAB
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants who are not able to or not willing to take atorvastatin will be given 10 mg ezetimibe oral tablets daily for the entire study period preferably at the same time each day.
Trial: NCT00300963
Drug: Talnetant
RxNorm normalized name: Talnetant
DrugBank: Talnetant (DB06429)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00317850
Drug: Gabapentin (Neurontin)
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03809650
Drug: macitentan 10 mg
RxNorm normalized name: macitentan 10 MG
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: macitentan 10 mg, film-coated tablet, oral use
Trial: NCT02243436
Drug: Brentuximab Vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab Vedotin, 0.9mg/kg, 1.2mg/kg, 1.8mg/kg, day 1
Trial: NCT02243436
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenose use, 40mg/m2/day, on days 1 to 4
Trial: NCT02243436
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous use, 25mg/m2/day, on days 1 to 4
Trial: NCT00678132
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00678132
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01363336
Drug: Nifedipine (Adalat CR, BAYA1040)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients who are administrated with Adalat CR for hypertension
Trial: NCT02024477
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg tablet once daily for 12 weeks
Trial: NCT01083407
Drug: 0.12% Chlorhexidine Digluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
Trial: NCT00541736
Drug: Nitroglycerine
RxNorm normalized name: Nitroglycerine
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min
Trial: NCT01623206
Drug: Desmopressin
RxNorm normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose groups: Group 1: 0.25 µg/kg/day; Group 2: 0.25 µg/kg/12 hours; Group 3: 0.50 µg/kg/12 hours; Group 4: 1 µg/kg/day; Group 5: 1 µg/kg/12 hours; Group 6: 2 µg/kg/day.~All groups will receive desmopressin intravenously, in a 15-20 minutes infusion, one or two times a day. The administration will be repeated 24 hours after the first infusion.
Trial: NCT03053115
Drug: Levothyroxin
RxNorm normalized name: Levothyroxin
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both cases and controls will take levothyroxine in the morning (entire dose for controls, reduced dose for cases)
Trial: NCT01475344
Drug: Human Fibrinogen Concentrate
RxNorm normalized name: Human fibrinogen concentrate, pasteurized
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / \> 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Fibrinogen Concentrate: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8).
Trial: NCT01902381
Drug: 6,8-bis(benzylthio)octanoic acid
RxNorm normalized name: 6,8-bis(benzylthio)octanoic acid
DrugBank: Devimistat (DB12109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00791102
Drug: ASP-1001 nasal spray
RxNorm normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
Trial: NCT01026116
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 every-3-week for four cycles
Trial: NCT01026116
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175 mg/m2 every-3-week for four cycles followed by weekly paclitaxel (80 mg/m2) for 12 weeks
Trial: NCT00144378
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00689520
Drug: tinzaparin
RxNorm normalized name: Tinzaparin
DrugBank: Tinzaparin (DB06822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
Trial: NCT00377312
Drug: Parathyroid Hormone (1-34)
RxNorm normalized name: Transcon parathyroid hormone (1-34)
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PTH(1-34) IV given over a one week period
Trial: NCT00274066
Drug: Tiotropium + placebo
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00274066
Drug: Tiotropium + ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00274066
Drug: Tiotropium + fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04225247
Drug: Bifluorid 12
RxNorm normalized name: MANGANESE DIFLUORIDE
DrugBank: Manganese citrate (DB14495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: it is a fluoride varnish by VOCO.
Trial: NCT04225247
Drug: Xeno V+
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xeno V+ (by Dentsply) is a seventh generation bonding agents used as desensitizers in the present study.
Trial: NCT03709056
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol iv 2.0 mg/kg for induction, and 1.0 mg/kg top-ups for maintenance. 1.5 mg/kg for induction and 0.75mg/kg for maintenance in adults of 65-70 years old.
Trial: NCT02228772
Drug: MLN 9708
RxNorm normalized name: MLN-977
DrugBank: MLN-977 (DB05431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will received standard chemotherapy as well as MLN 9708 in escalating doses.
Trial: NCT02228772
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy dosage and duration
Trial: NCT02228772
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard chemotherapy dosage and duration
Trial: NCT01896921
Drug: Switch to Maraviroc + Raltegravir or Dolutegravir
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks
Trial: NCT01819428
Drug: NOV120101 (Poziotinib)
RxNorm normalized name: Poziotinib
DrugBank: Poziotinib (DB12114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOV120101 (Poziotinib)12 mg PO once daily until disease progression or unacceptable toxicity development
Trial: NCT01066897
Drug: Pramipexole
RxNorm normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will received increasing dose of pramipexole
Trial: NCT03126188
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.
Trial: NCT03126188
Drug: Dosulepin
RxNorm normalized name: Dosulepin
DrugBank: Dosulepin (DB09167)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks,and the patients will be continued on the same dose for a minimum period of 6 weeks.
Trial: NCT03126188
Drug: Venlafaxine
RxNorm normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
Trial: NCT00116584
Drug: heliox
RxNorm normalized name: Helixate
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuous heliox therapy
Trial: NCT00116584
Drug: oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuous oxygen therapy
Trial: NCT00411463
Drug: Seroquel
RxNorm normalized name: Seroquel
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be started at 100 mg/day titrated to a maximum of 800 mg /day~Day 1-BID doses totaling 100 mg/day, increased to 400 mg/day on Day 4 in increments of up to 100 mg/day in BID divided doses, by Day 6 begin titration up to a maximum dose of 800 mg/day in increments no greater than 200 mg/day.~This titration schedule may be adjusted based on the subject's response and ability to tolerate Seroquel.~Subjects who are unable to tolerate the study medications, or for whom the study medications are an inappropriate clinical choice, will be treated openly by a clinic physician according to the standard of care guidelines designated by the American Psychiatric Association (2002) for the treatment of bipolar disorder.
Trial: NCT04297839
Drug: Citrate Anticoagulation Solution
RxNorm normalized name: ANTICOAGULANT CITRATE DEXTROSE
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional citrate anticoagulation in extended hemodialysis sessions compared to the standard of care actually performed in these therapies (heparin or continuous saline infusion)
Trial: NCT02669888
Drug: Indigo naturalis ointment
RxNorm normalized name: indigo
DrugBank: Indigo (DB16862)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
Trial: NCT00523692
Drug: Etanercept, methotrexate and depomedrone
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (50mg weekly; subcutaneous) Methotrexate (7.5-25mg weekly; oral) Depomedrone (up to 120mg; intraarticular / intramuscular)
Trial: NCT00490919
Drug: Buprenorphine transdermal system
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal system 10 or 20 mcg/h worn for 7 days
Trial: NCT00433433
Drug: ABVD q4 weeks
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Doxorubicin 25 mg/m2 i.v. day 1 and 15; Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15; Vinblastine 6 mg/m2 i.v. day 1 and 15; Dacarbazine 375 mg/m2 i.v. day 1 and 15
Trial: NCT00433433
Drug: BEACOPP escalated q3 weeks
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 1250 mg/m2 i.v. day 1; Doxorubicin 35 mg/m2 i.v. day 1; Vincristine 1.4 mg/m2 i.v.(max.2mg) day 8; Bleomycin 10 mg/m2 i.v./i.m. day 8; Etoposide 200 mg/m2/ i.v. day 1 to 3; Procarbazine 100 mg/m2 orally day 1 to 7; Prednisone 40 mg/m2 orally day 1 to 14; G-CSF 5 mcg/kg s.c. day 9 to recovery leukocytes\>1.0x109/l
Trial: NCT03129360
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam is an atypical anticonvulsant that is frequently used in children and adults due to its superior tolerability, ease of use and excellent safety profile.